Cost-effectiveness and public health impact of using high dose quadrivalent influenza vaccine in the French older adults population
Switching to QIV HD in older adults was shown to be cost-effective, with even greater public health benefits at a higher coverage rate, regardless of the season severity.
Authors
- Fabián P. Alvarez (ORCID: https://orcid.org/0000-0003-3085-6275)
- J. Gaillat (ORCID: https://orcid.org/0000-0003-2581-1187)
- G. Gavazzi (ORCID: https://orcid.org/0000-0001-8375-7153)
- Lee Allard
- Hélène Bricout (ORCID: https://orcid.org/0000-0002-5439-8064)
- Anne Mosnier (ORCID: https://orcid.org/0000-0002-3173-1186)
- Odile Launay (ORCID: https://orcid.org/0000-0003-3242-7247)
- D. Proshenska
- F. Bianic (ORCID: https://orcid.org/0009-0004-2039-2459)
- Pascal Crépey (ORCID: https://orcid.org/0000-0003-1852-0752)
- Caroline de Courville (ORCID: https://orcid.org/0000-0001-9396-6071)
- MC Levant
Institutions
- Délégation Paris 5 (FR)
- École des Hautes Études en Santé Publique (FR)
- Université Paris Cité (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Sanofi (France) (FR)
- Université Rennes 2 (FR)
- Syneos Health (United States) (US)
- Centre Hospitalier Annecy Genevois (FR)
- Université de Rennes (FR)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1080/13696998.2024.2404331
- Citations
- 5
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.93